Additionally, the introduction of very effective anti-HER2 targeted therapy in HER2+ tumors and increasingly aggressive treatment in triple negative breast cancer also cause an increase in the pCR rates in these subtypes, widening the gap in pCR rates even more. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.